Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

INTRODUCTION: In patients with axial spondyloarthritis (axSpA), biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended to those with inadequate response or contraindications to non-steroidal anti-inflammatory drugs (NSAIDs). In case of failure of the first bDMARD, a switch withi...

Descripción completa

Detalles Bibliográficos
Autores principales: Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, Xenofon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528363/
https://www.ncbi.nlm.nih.gov/pubmed/32998926
http://dx.doi.org/10.1136/bmjopen-2020-039059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528363/
https://www.ncbi.nlm.nih.gov/pubmed/32998926
http://dx.doi.org/10.1136/bmjopen-2020-039059

Ejemplares similares